Selected strategies to fight pathogenic bacteria

J Enzyme Inhib Med Chem. 2023 Dec;38(1):2155816. doi: 10.1080/14756366.2022.2155816.

Abstract

Natural products and analogues are a source of antibacterial drug discovery. Considering drug resistance levels emerging for antibiotics, identification of bacterial metalloenzymes and the synthesis of selective inhibitors are interesting for antibacterial agent development. Peptide nucleic acids are attractive antisense and antigene agents representing a novel strategy to target pathogens due to their unique mechanism of action. Antisense inhibition and development of antisense peptide nucleic acids is a new approach to antibacterial agents. Due to the increased resistance of biofilms to antibiotics, alternative therapeutic options are necessary. To develop antimicrobial strategies, optimised in vitro and in vivo models are needed. In vivo models to study biofilm-related respiratory infections, device-related infections: ventilator-associated pneumonia, tissue-related infections: chronic infection models based on alginate or agar beads, methods to battle biofilm-related infections are discussed. Drug delivery in case of antibacterials often is a serious issue therefore this review includes overview of drug delivery nanosystems.

Keywords: Antimicrobials; biofilms; biopharmaceuticals; metalloenzymes; natural products.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents*
  • Bacteria
  • Biofilms
  • Peptide Nucleic Acids*

Substances

  • Peptide Nucleic Acids
  • Anti-Infective Agents
  • Anti-Bacterial Agents

Grants and funding

This review was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 951883 within SPRINGBOARD project.